This bill directs the Director of the Agency for Toxic Substances and Disease Registry (ATSDR) to enter into an agreement with the National Academies of Sciences, Engineering, and Medicine , or another appropriate entity, to periodically assess the health effects of per- and polyfluoroalkyl substances (PFAS) measurable in human tissues. The agreement requires the formulation of clinical recommendations based on these assessments. The initial assessment and recommendations must be completed within two years of the agreement, with updates occurring every five years or more frequently if deemed necessary by the Director based on scientific advancements. Importantly, the National Academies or designated entity must engage with PFAS-exposed communities to gather input on their experiences. Following these assessments and recommendations, the ATSDR Director is mandated to issue and disseminate up-to-date clinical guidance on addressing PFAS health effects. This guidance must be posted on the ATSDR public website and distributed to State and local public health authorities and relevant healthcare professionals. The initial guidance is due within five years of the agreement's entry, with subsequent updates and dissemination occurring every five years or more frequently as scientific understanding evolves.